2023 World Conference on Lung Cancer (Posters)-EP11.01. Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Does Histology Matter?

EP11.01. Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Does Histology Matter? - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate whether the histology of non-small cell lung cancer (NSCLC) impacts the outcomes of immune checkpoint inhibitor (IO) therapy. Previous studies have shown that squamous cell carcinoma (SCC) patients had worse survival outcomes compared to non-squamous cell carcinoma (nSCC) patients before the era of IO therapy. <br /><br />A systematic search of relevant randomized control trials (RCTs) published between January 2010 and December 2022 was conducted, along with an additional search of ASCO and ESMO conferences. The eligible studies included phase II/III RCTs in NSCLC patients treated with IO-based therapies, regardless of treatment lines. The outcomes of interest included overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and objective response rate (ORR).<br /><br />A total of 25 studies were identified, which included 4,398 SCC patients and 9,773 nSCC patients. The results showed that IOs were associated with improved OS, PFS, and ORR in both SCC and nSCC patients. There was no significant difference in these outcomes between the two histological subtypes. This finding suggests that IO therapy may have helped bridge the gap in survival outcomes between SCC and nSCC by targeting a shared immune mechanism.<br /><br />Further analysis of the immunologic landscape of SCC and nSCC, as well as subset analysis based on PD-L1 expression, is warranted. Overall, this study demonstrates that histology does not impact the outcomes of IO-based therapy in NSCLC patients, highlighting the potential effectiveness of IOs in treating both SCC and nSCC.

Asset Subtitle

Khalil Choucair

Meta Tag

Speaker Khalil Choucair

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

non-small cell lung cancer

NSCLC

histology

immune checkpoint inhibitor

IO therapy

squamous cell carcinoma

SCC

non-squamous cell carcinoma

nSCC

randomized control trials